#1 Clinical Trials Search in Europe

Study on Dostarlimab Immunotherapy for Patients with Localized Gastric Cancer with Deficient Mismatch Repair or High Microsatellite Instability

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of stomach cancer known as gastric adenocarcinoma, specifically in cases where the cancer is localized and has certain genetic characteristics called deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H). The treatment being tested is an immunotherapy drug called Dostarlimab, which is also known by its code names WBP-285 and TSR-042. This drug is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Dostarlimab is in treating this type of cancer. Participants in the study will receive the drug and will be monitored over a period of time to see how their cancer responds. The study will look at whether the cancer stops growing or shrinks, and whether patients can avoid surgery to remove the tumor. The study will also assess the safety of the drug and any side effects that may occur.

Participants will undergo regular check-ups, including medical tests and scans, to track their progress. The study aims to determine if Dostarlimab can help patients live longer without their cancer getting worse. This research is important for understanding new ways to treat gastric adenocarcinoma and potentially improve outcomes for patients with this condition.

1 Joining the study

Upon joining the study, the patient will be informed about the trial’s objectives and procedures.

The patient must provide signed and dated informed consent to participate.

2 Initial assessments

The patient will undergo a series of initial assessments to confirm eligibility, including liver and kidney function tests, blood tests, and imaging studies such as CT scans.

A biopsy of the primary tumor will be required to confirm the tumor’s status as deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H).

3 Treatment initiation

The patient will begin treatment with dostarlimab, administered as an intravenous infusion.

The dosage is 500 mg, and the frequency and duration of administration will be determined by the study protocol.

4 Monitoring and follow-up

The patient will have regular follow-up visits to monitor the response to treatment and any side effects.

These visits will include physical examinations, blood tests, imaging studies, and possibly additional biopsies.

5 Evaluation of response

At one year from the start of therapy, the patient’s response will be evaluated to determine if there is a clinical complete response (cCR).

This evaluation will include checking for the absence of disease progression and negative biopsy results.

6 Continuation or conclusion of treatment

Based on the evaluation results, the patient may continue with the treatment or conclude participation in the study.

Further treatment decisions will be made according to the study protocol and the patient’s health status.

Who Can Join the Study?

  • The patient must be able to give signed and dated informed consent.
  • The patient must have adequate liver function, which means certain liver-related blood tests should be within specific limits.
  • The patient must have blood clotting tests within normal limits, unless they are on blood-thinning medication and their levels are considered safe by the doctor.
  • The patient must have a tumor assessment using a CT scan of the chest, abdomen, and pelvis, showing no spread of cancer or non-surgical disease.
  • Female patients must not be pregnant or breastfeeding.
  • Male patients must agree to certain conditions during the study and for 4 months after the last dose of the study drug.
  • The patient must provide samples of the primary tumor tissue, which are collected during an upper gastrointestinal (UGI) endoscopy, along with images.
  • The patient must be willing and able to attend scheduled visits, follow the treatment plan, and undergo necessary tests and procedures.
  • The patient must be registered in a National Health Care System.
  • The patient must have an ECOG PS of 0-1, which is a scale used to assess how well a patient can perform daily activities.
  • The patient must be between 18 and 75 years old. Patients over 75 can participate if they meet additional conditions, such as having a certain score on a health questionnaire and being eligible for surgery.
  • The patient must have a specific type of stomach cancer confirmed by tests, without cancer spread to other parts of the body.
  • The patient must not have cancer spread to the lining of the abdomen, unless further tests are done if there is doubt.
  • The patient must not have received previous treatment for localized stomach cancer.
  • The patient’s tumor must have specific genetic characteristics known as dMMR/MSI-H.
  • The patient must have adequate blood cell counts, including a certain level of neutrophils, platelets, and hemoglobin.
  • The patient must have adequate kidney function, with specific levels of creatinine and clearance rate.

Who Cannot Join the Study?

  • Patients who have had surgery to remove the tumor cannot participate.
  • Patients who have experienced disease progression, meaning the cancer has gotten worse or spread, are not eligible.
  • Patients with positive biopsies, which means tests show cancer cells are still present, cannot join the study.
  • Patients who do not show improvement in their endoscopy results, which is a test that looks inside the body, are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
IRCCS Humanitas Research Hospital Rozzano Italy
Centre Hospitalier Universitaire De Lille Lille France
Centre Hospitalier Regional Et Universitaire De Brest Brest France

Other Sites

Site Name City Country Status
Istituto Oncologico Veneto Padua Italy
Azienda Sanitaria Universitaria Friuli Centrale Udine Italy
Hopital Saint Antoine Paris France
Azienda Unita Sanitaria Locale Della Romagna Faenza Italy
Centre Hospitalier Universitaire De Poitiers Poitiers France
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Groupe Hospitalier Rance Emeraude Saint-Malo France
Iqsktnjl Rxhjtwus Dj Ceocgz Dg Mwydwbwtcds Montpellier France
Bgyfkycg Uncurcisvp Hbaimhnt Cozxwa Besançon France
Caklik Lndt Boemzg Lyon France
Cswond Hyrmwmjcsek Ukyudnnimveom Rnaih Reims France
Inemragm Mbnogupszo Mmruefqzpn Paris France
Huehzao Hpwon Mnvsef &qwyidp 1 rug Ghvsfte Eybygj Creteil France
Ifsmsoyb Pjiuvvzarujdpfg Cdksmo Czpsmq Marseille France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
30.10.2023
Italy Italy
Recruiting
30.10.2023

Trial locations

Investigated drugs:

Dostarlimab is an immunotherapy medication used in this clinical trial. It is designed to help the body’s immune system recognize and attack cancer cells. In this study, it is being tested for its effectiveness in treating patients with a specific type of stomach cancer that has certain genetic characteristics, known as deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H). The goal is to see if patients can achieve a complete response to the treatment without needing surgery.

Investigated diseases:

Metastatic Gastric Cancer – This is a type of cancer that begins in the stomach and has spread to other parts of the body. It often starts in the cells lining the stomach and can invade nearby organs or travel through the bloodstream to distant sites. As the disease progresses, it can cause symptoms such as weight loss, stomach pain, and difficulty swallowing. The spread of cancer cells to other organs, such as the liver or lungs, is a key characteristic of its metastatic nature. This progression can lead to a variety of complications depending on the organs affected. The disease is typically diagnosed at an advanced stage due to its subtle early symptoms.

Trial ID:
2023-506102-39-00
Protocol code:
DEWI G-123
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain

  • Study of intraperitoneal paclitaxel combined with systemic therapy versus systemic therapy alone for patients with gastric cancer and peritoneal metastases

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy The Netherlands Norway Sweden